The role of MAPK-ERK pathway in 67-kDa laminin receptor-induced FasL expression in human cholangiocarcinoma cells

Digestive Diseases and Sciences

Volumn 55, Issue 10, 2010, Pages 2844-2852

  Duan, Shi Gang ^a   Cheng, Long ^a   Li, Da Jiang ^a   Zhu, Jin ^a   Xiong, Yan ^a   Li, Xiao Wu ^a   Wang, Shu Guang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cholangiocarcinoma; Fas ligand (FasL); Laminin receptor; MAPK ERK kinases

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; FAS LIGAND; LAMININ; LAMININ RECEPTOR; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SERINE; SMALL INTERFERING RNA; ENZYME INHIBITOR; FASLG PROTEIN, HUMAN; FLAVONOID; LAMR1 PROTEIN, HUMAN; MYC PROTEIN; MYC PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CARCINOMA CELL; CYTOTOXICITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LYMPHOCYTE; ONCOGENE C MYC; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; UPREGULATION; BILE DUCT TUMOR; COCULTURE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; INTRAHEPATIC BILE DUCT; LEUKEMIA CELL LINE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; SIGNAL TRANSDUCTION;

APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; COCULTURE TECHNIQUES; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FAS LIGAND PROTEIN; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JURKAT CELLS; LUCIFERASES; MAP KINASE SIGNALING SYSTEM; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, LAMININ; RNA, SMALL INTERFERING; TRANSFECTION; UP-REGULATION;

EID: 77957917241     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-1121-9     Document Type: Article

References (45)

1. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449-1456.
2. Walker PR, Saas P, Dietrich PY. Tumor expression of Fas ligand (CD95L) and the consequences. Curr Opin Immunol. 1998;10:564-572.
3. Asanuma K, Tsuji N, Endoh T, Yagihashi A, Watanabe N. Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells. J Immunol. 2004;172:3922-3929.
4. Whiteside TL. The role of death receptor ligands in shaping tumor microenvironment. Immunol Invest. 2007;36:25-46.
5. Adachi K, Fujino M, Kitazawa Y, et al. Exogenous expression of Fas-ligand or CrmA prolongs the survival in rat liver transplantation. Transplant Proc. 2006;38:2710-2713.
6. Li Z, Zhang L, Zou S. The "Fas counterattack": a mechanism for immune evasion in human hilar cholangiocarcinomas. Zhonghua Yi Xue Za Zhi. 2002;82:606-609.
7. Gao ZF, Li TY, Gao YH, et al. Overexpression of laminin receptor in up regulating Fas ligand in cells of cholangiocarcinoma. Chin J Dig Surg. 2008;6:53-55.
8. Ryan AE, Shanahan F, O'Connell J, Houston AM. Addressing the "Fas counterattack" controversy: blocking Fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res. 2005;65:9817-9823.
9. O'Callaghan G, Kelly J, Shanahan F, Houston A. Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells. Br J Cancer. 2008;99:502-512.
10. Bennett MW, O'Connell J, O'Sullivan GC, et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol. 1998;160:5669-5675.
11. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996;184:1075-1082.
12. Menard S, Tagliabue E, Colnaghi MI. The 67 kDa laminin receptor as a prognostic factor in human cancer. Breast Cancer Res Treat. 1998;52:137-145.
13. Satoh K, Narumi K, Abe T, et al. Diminution of 37-kDa laminin binding protein expression reduces tumour formation of murine lung cancer cells. Br J Cancer. 1999;80:1115-1122.
14. Vacca A, Ribatti D, Roncali L, et al. Melanocyte tumor progression is associated with changes in angiogenesis and expression of the 67-kilodalton laminin receptor. Cancer. 1993;72:455-461.
15. Sanjuan X, Fernandez PL, Miquel R, et al. Overexpression of the 67-kD laminin receptor correlates with tumour progression in human colorectal carcinoma. J Pathol. 1996;179:376-380.
16. Givant-Horwitz V, Davidson B, Reich R. Laminin-induced signaling in tumor cells. Cancer Lett. 2005;223:1-10.
17. Li D, Chen J, Gao Z, et al. 67-kDa laminin receptor in human bile duct carcinoma. Eur Surg Res. 2009;42:168-173.
18. Gloe T, Riedmayr S, Sohn HY, Pohl U. The 67-kDa lamininbinding protein is involved in shear stress-dependent endothelial nitric-oxide synthase expression. J Biol Chem. 1999;274:15996-16002.
19. Givant-Horwitz V, Davidson B, Reich R. Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor. Cancer Res. 2004;64:3572-3579.
20. Choi C, Xu X, Oh JW, et al. Fas-induced expression of chemokines in human glioma cells: involvement of extracellular signalregulated kinase 1/2 and p38 mitogen-activated protein kinase. Cancer Res. 2001;61:3084-3091.
21. Shinohara H, Yagita H, Ikawa Y, Oyaizu N. Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. Cancer Res. 2000;60:1766-1772.
22. Kavurma MM, Khachigian LM. Signaling and transcriptional control of Fas ligand gene expression. Cell Death Differ. 2003;10:36-44.
23. Sansom OJ, Meniel VS, Muncan V, et al. Myc deletion rescues Apc deficiency in the small intestine. Nature. 2007;446:676-679.
24. Bermudez Y, Yang H, Cheng JQ, Kruk PA. Pyk2/ERK 1/2 mediate Sp1- and c-Myc-dependent induction of telomerase activity by epidermal growth factor. Growth Factors. 2008;26: 1-11.
25. Wang SG, Chen CH, Li DJ, Li K. Effect of down regulation of laminin receptor on urokinase-type plasminogen activator expression in human bile duct carcinoma cells. Zhonghua Yi Xue Za Zhi. 2004;84:1642-1644.
26. Kasibhatla S, Brunner T, Genestier L, et al. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell. 1998;1:543-551.
27. Brunner T, Kasibhatla S, Pinkoski MJ, et al. Expression of Fas ligand in activated T cells is regulated by c-Myc. J Biol Chem. 2000;275:9767-9772.
28. Kasibhatla S, Beere HM, Brunner T, et al. A 'non-canonical' DNA-binding element mediates the response of the Fas-ligand promoter to c-Myc. Curr Biol. 2000;10:1205-1208.
29. Chanprasert S, Geddis AE, Barroga C, et al. Thrombopoietin (TPO) induces c-myc expression through a PI3 K- and MAPKdependent pathway that is not mediated by Akt, PKCzeta or mTOR in TPO-dependent cell lines and primary megakaryocytes. Cell Signal. 2006;18:1212-1218.
30. Wang CL, Ng TB, Cao XH, et al. CLP induces apoptosis in human leukemia K562 cells through Ca(2 ?) regulating extracellular- related protein kinase ERK activation. Cancer Lett. 2009;276:221-227.
31. Patarroyo M, Tryggvason K, Virtanen I. Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol. 2002;12:197-207.
32. Sasaki T, Fassler R, Hohenester E. Laminin: the crux of basement membrane assembly. J Cell Biol. 2004;164:959-963.
33. Wehrle-Haller B, Imhof BA. Integrin-dependent pathologies. J Pathol. 2003;200:481-487.
34. Kohno M, Pouyssegur J. Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs. Prog Cell Cycle Res. 2003;5:219-224.
35. Pereira DB, Carvalho AP, Duarte CB. Non-specific effects of the MEK inhibitor PD098059 and U0126 on glutamate release from hippocampal synaptosomes. Neuropharmacology. 2002;42:9-19.
36. Sears R, Nuckolls F, Haura E, et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14:2501-2514.
37. Berno V, Porrini D, Castiglioni F, et al. The 67-kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1. Endocr Relat Cancer. 2005;12:393-406.
38. Ghosh S, Stack MS. Proteolytic modification of laminins: functional consequences. Microsc Res Tech. 2000;51:238-246.
39. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol. 2004;16:558-564.
40. Schenk S, Quaranta V. Tales from the crypt[ic] sites of the extracellular matrix. Trends Cell Biol. 2003;13:366-375.
41. Eberle J, Fecker LF, Hossini AM, et al. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. Oncogene. 2003;22:9131-9141.
42. Gao CF, Xie Q, Su YL, et al. Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci USA. 2005;102:10528-10533.
43. Taj MM, Tawil RJ, Engstrom LD, et al. Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells. Prostate. 2001;47:194-204.
44. Wang YH, Liu S, Zhang G, et al. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res. 2005;7:R220-R228.
45. Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002;297: 102-104.